Alirocumab is indicated for:
Primary heterozygous familial hypercholesterolaemia, primary non-familial hypercholesterolaemia, mixed dyslipidaemia
Irrespective of gender only Adults (18 years old or older)
Alirocumab is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
The effect of alirocumab on cardiovascular morbidity and mortality has not yet been determined.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Subcutaneous - 75-150 mg once every 2 weeks
Treatment 2: Subcutaneous - 150-300 mg once every 4 weeks
Active ingredient Alirocumab is contraindicated in the following cases: